Drug Trial Radar · NCT00732524
Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA
Last checked: Nov 20, 2026Latest source record: Aug 12, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Sep 2004
Primary completion
Apr 2006
Study completion Apr 2006
Sponsor
- Lead sponsor
- Cook County HealthGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Aug 12, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare two simple and safe emergency department discharge therapy for Type 2 Diabetes patients with severe hyperglycemia and with no indications for inpatient admission.
Conditions
- Type 2 Diabetes
Interventions
GlipizideDrug
Glipizide XL 10 mg once daily 30 mins before breakfast
Glipizide and GlargineDrug
Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome was the patients' ability to avoid repeat ED visits or hospitalization in either of the discharge regimens.Time frame: 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
John H Stroger Hospital Of Cook County
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.